(Q37114112)

18 August 2017

1 reference

title

Progress in neuroprotection in Parkinson's disease (English)

1 reference

18 August 2017

1 reference

1

A H V Schapira

1 reference

18 August 2017

1 April 2008

1 reference

European Journal of Neurology

18 August 2017

1 reference

18 August 2017

15 Suppl 1

1 reference

18 August 2017

5-13

1 reference

Epidemiology of Parkinson's disease

18 August 2017

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2008.02055.X

Non-motor symptoms of Parkinson's disease: diagnosis and management

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2008.02055.X

Treatment options in the modern management of Parkinson disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2008.02055.X

Novel pharmacological targets for the treatment of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2008.02055.X

Science, medicine, and the future: Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2008.02055.X

The importance of LRRK2 mutations in Parkinson disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2008.02055.X

Identification of a novel LRRK2 mutation linked to autosomal dominant parkinsonism: evidence of a common founder across European populations

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2008.02055.X

The dardarin G 2019 S mutation is a common cause of Parkinson's disease but not other neurodegenerative diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2008.02055.X

Clinical features of LRRK2-associated Parkinson's disease in central Norway

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2008.02055.X

Comprehensive analysis of the LRRK2 gene in sixty families with Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2008.02055.X

G2019S LRRK2 mutation in French and North African families with Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2008.02055.X

Escaping Parkinson's disease: a neurologically healthy octogenarian with the LRRK2 G2019S mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2008.02055.X

The Parkinson disease causing LRRK2 mutation I2020T is associated with increased kinase activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2008.02055.X

Parkinson's disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2008.02055.X

Leucine-rich repeat kinase 2 (LRRK2) interacts with parkin, and mutant LRRK2 induces neuronal degeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2008.02055.X

Deprenyl protects dopamine neurons from the neurotoxic effect of 1-methyl-4-phenylpyridinium ion.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2008.02055.X

Rescue of dying neurons: A new action for deprenyl in MPTP parkinsonism

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2008.02055.X

Enhanced hydroxyl radical generation by 2'-methyl analog of MPTP: suppression by clorgyline and deprenyl

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2008.02055.X

Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2008.02055.X

The effect of deprenyl and levodopa on the progression of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2008.02055.X

Impact of sustained deprenyl (selegiline) in levodopa-treated Parkinson's disease: a randomized placebo-controlled extension of the deprenyl and tocopherol antioxidative therapy of parkinsonism trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2008.02055.X

Monoamine oxidase type B inhibitors in early Parkinson's disease: meta-analysis of 17 randomised trials involving 3525 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2008.02055.X

An anti-Parkinson's disease drug, N-propargyl-1(R)-aminoindan (rasagiline), enhances expression of anti-apoptotic bcl-2 in human dopaminergic SH-SY5Y cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2008.02055.X

The anti-Parkinson drug, rasagiline, prevents apoptotic DNA damage induced by peroxynitrite in human dopaminergic neuroblastoma SH-SY5Y cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2008.02055.X

A strong correlation exists between the distribution of retinal ganglion cells and nose length in the dog.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2008.02055.X

Contrasting neuroprotective and neurotoxic actions of respective metabolites of anti-Parkinson drugs rasagiline and selegiline

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2008.02055.X

A controlled, randomized, delayed-start study of rasagiline in early Parkinson disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2008.02055.X

Monoamine oxidase inhibitors--is it time to up the TEMPO?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2008.02055.X

Propargylamines induce antiapoptotic new protein synthesis in serum- and nerve growth factor (NGF)-withdrawn, NGF-differentiated PC-12 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2008.02055.X

Glyceraldehyde-3-phosphate dehydrogenase, the putative target of the antiapoptotic compounds CGP 3466 and R-(-)-deprenyl

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2008.02055.X

CGP 3466 protects dopaminergic neurons in lesion models of Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2008.02055.X

Systemic administration of the propargylamine CGP 3466B prevents behavioural and morphological deficits in rats with 6-hydroxydopamine-induced lesions in the substantia nigra.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2008.02055.X

TCH346 prevents motor symptoms and loss of striatal FDOPA uptake in bilaterally MPTP-treated primates

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2008.02055.X

TCH346 as a neuroprotective drug in Parkinson's disease: a double-blind, randomised, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2008.02055.X

Mitochondrial membrane permeabilization in cell death

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2008.02055.X

21 January 2018

Mitochondrial disease

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2008.02055.X

Mitochondrial respiratory chain disorders II: neurodegenerative disorders and nuclear gene defects

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2008.02055.X

Mitochondrial respiratory chain disorders I: mitochondrial DNA defects

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2008.02055.X

Mitochondrial function and parental sex effect in Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2008.02055.X

Biochemical abnormalities and excitotoxicity in Huntington's disease brain.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2008.02055.X

Effects of coenzyme Q10 in early Parkinson disease: evidence of slowing of the functional decline

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2008.02055.X

A randomized clinical trial of coenzyme Q10 and GPI-1485 in early Parkinson disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2008.02055.X

Randomized, double-blind, placebo-controlled trial on symptomatic effects of coenzyme Q(10) in Parkinson disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2008.02055.X

Creatine and cyclocreatine attenuate MPTP neurotoxicity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2008.02055.X

A randomized, double-blind, futility clinical trial of creatine and minocycline in early Parkinson disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2008.02055.X

Creatine supplementation in Parkinson disease: a placebo-controlled randomized pilot trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2008.02055.X

Apomorphine is a highly potent free radical scavenger in rat brain mitochondrial fraction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2008.02055.X

The dopamine agonist cabergoline provides neuroprotection by activation of the glutathione system and scavenging free radicals

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2008.02055.X

Pergolide scavenges both hydroxyl and nitric oxide free radicals in vitro and inhibits lipid peroxidation in different regions of the rat brain.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2008.02055.X

Dopamine D2 receptor-mediated antioxidant and neuroprotective effects of ropinirole, a dopamine agonist.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2008.02055.X

Neuroprotection by pramipexole against dopamine- and levodopa-induced cytotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2008.02055.X

Pharmacological approaches to counter the toxicity of Dopa.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2008.02055.X

Pramipexole protects against apoptotic cell death by non-dopaminergic mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2008.02055.X

Pramipexole protects against MPTP toxicity in non-human primates

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2008.02055.X

Involvement of dopamine D(2)/D(3) receptors and BDNF in the neuroprotective effects of S32504 and pramipexole against 1-methyl-4-phenylpyridinium in terminally differentiated SH-SY5Y cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2008.02055.X

Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2008.02055.X

Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL-PET study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2008.02055.X

Neuroprotection in Parkinson disease: mysteries, myths, and misconceptions

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2008.02055.X

Slowing Parkinson's disease progression: recent dopamine agonist trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2008.02055.X

Levodopa and the progression of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2008.02055.X

Initial agonist treatment of Parkinson disease: a critique

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2008.02055.X

Agonists vs levodopa in PD: the thrilla of whitha

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2008.02055.X

Chronic, controlled GDNF infusion promotes structural and functional recovery in advanced parkinsonian monkeys

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2008.02055.X

Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2008.02055.X

Clinicopathological findings following intraventricular glial-derived neurotrophic factor treatment in a patient with Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2008.02055.X

Randomized, double-blind trial of glial cell line-derived neurotrophic factor (GDNF) in PD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2008.02055.X

Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2008.02055.X

Continuing trials of GDNF in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2008.02055.X

Timing of treatment initiation in Parkinson's disease: a need for reappraisal?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2008.02055.X

Disease modification in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2008.02055.X

Chronic levodopa is not toxic for remaining dopamine neurons, but instead promotes their recovery, in rats with moderate nigrostriatal lesions

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2008.02055.X

A clinic-based study of the LRRK2 gene in Parkinson disease yields new mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2008.02055.X

LRRK2 mutations in Parkinson disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2008.02055.X

A frequent LRRK2 gene mutation associated with autosomal dominant Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2008.02055.X

10.1111/J.1468-1331.2008.02055.X

21 January 2018

Identifiers

DOI

1 reference

18 August 2017

1 reference

PubMed ID

18353131